A hormone treatment called tesamorelin raises IGF-1 hormone levels more than a placebo in people with HIV at 2 weeks, 3 months, and 6 months of treatment.
Scientific Claim
Tesamorelin increases IGF-1 levels significantly at 2 weeks, 3 months, and 6 months compared to placebo in HIV-infected adults.
Original Statement
“Changes from baseline in IGF-1 and IGF-1 Z-scores were significantly different between treatment groups at 2 weeks, 3 months, and 6 months of treatment (see Supplemental Table 6).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
As a randomized controlled trial, this study design supports causal language for this secondary outcome. The verb 'increases' is appropriate for the observed effect.
Evidence from Studies
Supporting (1)
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.